{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:44:57Z","timestamp":1761169497735,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jval.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T07:34:13Z","timestamp":1651908853000},"page":"1685-1695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Neda","family":"Alrawashdh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Erstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joann","family":"Sweasy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2022.04.001_bib1","first-page":"7","article-title":"Cancer statistics, 2021 [published correction appears in CA Cancer J Clin. 2021;71(4):359]","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.jval.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11912-020-0893-0","article-title":"Chronic lymphocytic leukaemia in 2020: the future has arrived","volume":"22","author":"Milne","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.jval.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bjh.16042","article-title":"Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients","volume":"187","author":"Hu","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jval.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jval.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41408-018-0131-2","article-title":"Chronic lymphocytic leukemia treatment algorithm 2018","volume":"8","author":"Parikh","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jval.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9980","key":"10.1016\/j.jval.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jval.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2022.04.001_bib9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3324\/haematol.2017.170480","article-title":"Rituximab plus Bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet","year":"2018","journal-title":"Haematologica"},{"issue":"10129","key":"10.1016\/j.jval.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jval.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/17474086.2017.1398642","article-title":"Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia","volume":"10","author":"Innocenti","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"suppl 4","key":"10.1016\/j.jval.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.13493","article-title":"Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil","volume":"47","author":"Tam","year":"2017","journal-title":"Intern Med J"},{"issue":"15","key":"10.1016\/j.jval.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jval.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.jval.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10232","key":"10.1016\/j.jval.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial [published correction appears in Lancet. 2020;395(10238):1694]","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2022.04.001_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2019;20(1):e10]","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.jval.2022.04.001_bib18","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1080\/10428194.2018.1543882","article-title":"The magnitude of improvement in progression-free survival with targeted therapy in relapsed\/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis","volume":"60","author":"Molica","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jval.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/asheducation-2016.1.149","article-title":"Prognostication of chronic lymphocytic leukemia in the era of new agents","volume":"1","author":"Eichhorst","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.jval.2022.04.001_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/PPO.0000000000000417","article-title":"The shifting paradigm in chronic lymphocytic leukemia: is chemotherapy still relevant?","volume":"25","author":"Jain","year":"2019","journal-title":"Cancer J"},{"issue":"5","key":"10.1016\/j.jval.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2022.04.001_bib23","first-page":"185","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J\u00a0Natl Compr Canc Network"},{"issue":"11","key":"10.1016\/j.jval.2022.04.001_bib24","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2018.208603","article-title":"Sequential and combination treatments with novel agents in chronic lymphocytic leukemia","volume":"104","author":"F\u00fcrstenau","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jval.2022.04.001_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/PPO.0000000000000410","article-title":"Targeted therapies in chronic lymphocytic leukemia: is 2 (or 3) better than 1?","volume":"25","author":"Ujjani","year":"2019","journal-title":"Cancer J"},{"issue":"11","key":"10.1016\/j.jval.2022.04.001_bib26","doi-asserted-by":"crossref","first-page":"e820","DOI":"10.1016\/j.clml.2021.06.010","article-title":"Comparative efficacy of first-line treatments of chronic lymphocytic leukemia: network meta-analyses of survival curves","volume":"21","author":"Alrawashdh","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jval.2022.04.001_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"3-4","key":"10.1016\/j.jval.2022.04.001_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jval.2022.04.001_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.jval.2022.04.001_bib30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.clinthera.2016.02.005","article-title":"Cost-effectiveness of first-line chronic lymphocytic leukemia treatments when full-dose fludarabine is unsuitable","volume":"38","author":"Soini","year":"2016","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.jval.2022.04.001_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jval.2015.12.018","article-title":"Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy","volume":"19","author":"Becker","year":"2016","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2022.04.001_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-015-0367-7","article-title":"Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature","volume":"34","author":"Frey","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2022.04.001_bib33","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jval.2022.04.001_bib34","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia [published correction appears in J Clin Oncol. 2010;28(22):3670]","volume":"28","author":"Wierda","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jval.2022.04.001_bib35","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jval.2022.04.001_bib36","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"10.1016\/j.jval.2022.04.001_bib37","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"author":"Helwick","key":"10.1016\/j.jval.2022.04.001_bib38"},{"issue":"7","key":"10.1016\/j.jval.2022.04.001_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10198-017-0942-2","article-title":"Health economic evaluation of Rivaroxaban in elective cardioversion of atrial fibrillation","volume":"19","author":"Jacobs","year":"2018","journal-title":"Eur J Health Econ"},{"issue":"12","key":"10.1016\/j.jval.2022.04.001_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.jval.2022.04.001_bib43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1634\/theoncologist.2018-0019","article-title":"Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin\u2019s lymphoma","volume":"24","author":"Reyes","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jval.2022.04.001_bib44","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","article-title":"Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival","volume":"56","author":"Kosmas","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jval.2022.04.001_bib45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40258-019-00496-1","article-title":"Phase I\/II clinical trial-based early economic evaluation of acalabrutinib for relapsed chronic lymphocytic leukaemia","volume":"17","author":"Vreman","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"10.1016\/j.jval.2022.04.001_bib46","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","article-title":"Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia","volume":"14","author":"Tolley","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2022.04.001_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2022.04.001_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12955-018-0994-8","article-title":"Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients","volume":"16","author":"Paracha","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/j.jval.2022.04.001_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11136-010-9591-y","article-title":"Factors determining utility measured with the EQ-5D in patients with atrial fibrillation","volume":"19","author":"Berg","year":"2010","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.jval.2022.04.001_bib50","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ejh.13007","article-title":"Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia","volume":"100","author":"Casado","year":"2018","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.jval.2022.04.001_bib52","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.jval.2022.04.001_bib53","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2020005426","article-title":"A\u00a0predictive tool for early-stage CLL","volume":"135","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jval.2022.04.001_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"year":"2005","series-title":"Using Cost-Effectiveness Analysis to Improve Health Care","author":"Neumann","key":"10.1016\/j.jval.2022.04.001_bib55"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:26:55Z","timestamp":1761096415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522001966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1098301522001966"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.04.001","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}